Editas Medicine/EDIT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Editas Medicine

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Ticker

EDIT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gilmore O'Neill

Employees

265

Headquarters

Cambridge, United States

Editas Medicine Metrics

BasicAdvanced
$428M
Market cap
-
P/E ratio
-$2.10
EPS
2.05
Beta
-
Dividend rate
$428M
2.05342
$11.91
$4.91
1.9M
4.596
-36.74%
-54.30%
-42.55%
6.161
1.453
1.453
204.54%
33.96%
-4.87%

What the Analysts think about Editas Medicine

Analyst Ratings

Majority rating from 18 analysts.
Hold

Editas Medicine Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,627.27% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
-98.17%
Net income
-$62M
229.26%
Profit margin
-5,627.27%
17,861.28%

Editas Medicine Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.34%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.56
-$0.55
-$0.23
-$0.76
-
Expected
-$0.76
-$0.57
-$0.54
-$0.66
-$0.70
Surprise
-26.62%
-3.19%
-57.57%
14.34%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Editas Medicine stock?

Editas Medicine (EDIT) has a market cap of $428M as of June 19, 2024.

What is the P/E ratio for Editas Medicine stock?

The price to earnings (P/E) ratio for Editas Medicine (EDIT) stock is 0 as of June 19, 2024.

Does Editas Medicine stock pay dividends?

No, Editas Medicine (EDIT) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Editas Medicine dividend payment date?

Editas Medicine (EDIT) stock does not pay dividends to its shareholders.

What is the beta indicator for Editas Medicine?

Editas Medicine (EDIT) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Editas Medicine stock price target?

The target price for Editas Medicine (EDIT) stock is $15, which is NaN% below the current price of $. This is an average based on projections from 14 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Editas Medicine stock

Buy or sell Editas Medicine stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing